EBACW (European Biotech Acquisition) Asset Impairment Charge: $0.00 Mil (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBACW European Biotech Acquisition Corp EBACW
22 GF Score
Price $0.52
View Full Analysis

What is European Biotech Acquisition Asset Impairment Charge?

European Biotech Acquisition EBACW 22 Asset Impairment Charge is $0.00 Mil as of Dec. 2022. GuruFocus rates EBACW with a GF Score™ of 22/100.

European Biotech Acquisition's Asset Impairment Charge for the three months ended in Dec. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

European Biotech Acquisition Asset Impairment Charge Related Terms

European Biotech Acquisition Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for European Biotech Acquisition's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition Asset Impairment Charge Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Asset Impairment Charge
0.00 0.00

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Asset Impairment Charge Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EBACW
22GF Score
European Biotech Acquisition Corp EBACW
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

European Biotech Acquisition Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Asset Impairment Charge of $0.00 Mil mean?
European Biotech Acquisition (EBACW) has a Asset Impairment Charge of $0.00 Mil as of Dec. 2022.
Is European Biotech Acquisition's Asset Impairment Charge too high?
European Biotech Acquisition's current Asset Impairment Charge is $0.00 Mil. Overall, European Biotech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does European Biotech Acquisition's Asset Impairment Charge compare to CNTQ and LION?
European Biotech Acquisition's Asset Impairment Charge of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Diversified Financial Services company?
A good Asset Impairment Charge depends on the Diversified Financial Services industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. European Biotech Acquisition's current Asset Impairment Charge is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Biotech Acquisition stock overvalued right now?
European Biotech Acquisition (EBACW) has a current Asset Impairment Charge of $0.00 Mil. The current Asset Impairment Charge is $0.00 Mil. European Biotech Acquisition's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For European Biotech Acquisition (EBACW), the current Asset Impairment Charge is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

European Biotech Acquisition Business Description

Address EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EBACW

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price